StreetAlpha.app
Home › Stocks › AZR

Azora Therapeutics, Inc. (DE) (AZR)

$3.85
▼ −0.52%
LAST CLOSE · NOV 20

Azora Therapeutics develops AD04, an investigational treatment for alcohol use disorder and other addiction and related disorders. It last closed at $3.85 on Nov 20, down 0.52% on the day. For the quarter ended Sep 2026, AZR reported EPS of -$4.52. Over the last 12 months AZR insiders bought $106K of stock on the open market and sold $0, according to SEC Form 4 filings.

AI Auto Pilots
Is AZR in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold AZR.

Key Stats

Last 12 months
Results
Net income
−$120.6M
EPS (diluted)
−$17.99
Valuation
Market cap
$55.0M
14.3M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$22.0M
At Sep 30
Shareholder equity
−$21.1M
Shares outstanding
14.3M
At Nov 9
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$19.4M−$19.4MFY2021FY2022: −$12.7M−$12.7MFY2022FY2023: −$5.1M−$5.1MFY2023FY2024: −$13.2M−$13.2MFY2024FY2025: −$8.0M−$8.0MFY2025

From AZR's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Next report
—
No date on file yet
Reported EPS
-$4.52
Quarter ended Sep 2026
Year ago EPS
-$2.02
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$65.44Dec '24Mar 2025: -$8.52Mar '25Jun 2025: -$4.61Jun '25Sep 2025: -$2.02Sep '25Dec 2025: -$0.58Dec '25Mar 2026: -$1.48Mar '26Jun 2026: -$11.25Jun '26Sep 2026: -$4.52Sep '26Latest -$4.52
Revenue by quarter
Not enough quarters on file yet.
StreetAlpha's call on AZRStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on AZR
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on AZR
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Whale Options Flow

90D
Whale options flow for AZRHow many large options trades hit AZR, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

AZR Insider Trading

All filings →
Insider trading · 12 months
Insiders are buying
Bought$106K3 buys · 1 insider
Sold$00 sales · 0 insiders
2026-06 bought $65K2026-07 bought $41KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Jul 16Coastlands Capital LP10% ownerBuy3,233$2.69$9K
Jul 10Coastlands Capital LP10% ownerBuy11,753$2.78$33K
Jun 29Coastlands Capital LP10% ownerBuy25,000$2.60$65K
Every insider buy and sale for AZR over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See AZR insider trades →

From SEC Form 4 filings by AZR's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether AZR is in one of them and how their past AZR trades turned out.

AZR in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered AZR in an article yet. Here's the latest on the wider market.

About Azora Therapeutics, Inc. (DE)

Azora Therapeutics is a clinical stage biopharmaceutical company that develops treatments for addiction and related disorders. Its lead candidate, AD04, is being developed for alcohol use disorder in patients with certain genetic profiles, identified using a companion genetic test. The company's main focus is completing clinical development for AD04 to meet regulatory requirements in the United States and Europe. It has no products approved for sale yet and is based in Encino, California.

Headquarters
Encino, CA